Terumo Corporation (TRUMY) Stock Price & Analysis
Terumo Corporation (TRUMY) — price $14.44 (+1.40%), as of the Oct 5, 2026 trading session; market cap $21.3B. Expected results Nov 11, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Terumo Corporation · TRUMY · Healthcare · Medical - Devices
Terumo Corporation is a global medical technology company dedicated to the manufacturing and sale of a wide array of medical products and equipment, operating through three distinct business segments: Cardiac and Vascular…
Price as of Oct 5, 2026
Key Statistics
No publishable V2 score is available for this stock yet.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $14.44 | |
| Change on the day | +1.40% | |
| 52-week range | $12.08 – $17.81 | |
| Market capitalisation | $21.3B | |
| Price / earnings (trailing) | 20.93 | |
| Shares traded on the day | 3.7K | |
| Beta (volatility vs the S&P 500) | 0.23 | |
| Dividends per share (last 12 months) | $0.12 | |
| Dividend yield (last 12 months) | 0.80% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · in line with the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Chronological order, not a duration scale. The provider's estimated date can change.
What to watch nextOther perspectives
Council score for Terumo (TRUMY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 6, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Oct 6, 2026, except a card that shows its own read date.
Watch the TRUMY film — every key number, told as a short cinematic story
~2 min · open the film
What is Terumo (TRUMY), and what does it report?
Short answer · as of
Terumo Corporation is a global medical technology company dedicated to the manufacturing and sale of a wide array of medical products and equipment, operating through three distinct business segments: Cardiac and Vascular… Healthcare / Medical Devices Headquarters: 2-44-1, Hatagaya, Tokyo, TY, 151-0072, JP. It employs 30,207 people and is led by Hikaru Samejima. In Q1 FY2027 it reported revenue of $1.97B and net income of $445M. The market values it at $21.3B.
What do the latest results show for Terumo (TRUMY)?
Short answer · as of
The most recent reported quarter, Q1 FY2027, carried revenue of $1.97B. Against analyst estimates the company has EPS beat 2 of 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $1.96B Aug 7, 2026
- Latest report · revenue estimate
- $1.84B Aug 7, 2026
- Latest report · revenue vs estimate
- Above estimate Aug 7, 2026
- Latest report · EPS vs estimate
- Above estimate Aug 7, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 7, 2026 | $1.96B | $1.84B | $0.3000 | $0.1700 |
| May 15, 2026 | $1.89B | $1.84B | $0.1100 | $0.1100 |
| Feb 13, 2026 | $1.93B | $1.86B | $0.1400 | $0.1453 |
| Nov 12, 2025 | $1.78B | $1.75B | $0.1541 | $0.1611 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 FY2027 | $1.97B | $445M | $0.30 (diluted) |
| Q4 FY2026 | $1.93B | $170M | $0.12 (diluted) |
| Q3 FY2026 | $1.91B | $210M | $0.14 (diluted) |
| Q2 FY2026 | $1.77B | $225M | $0.15 (diluted) |
What are the financial strengths and risks for Terumo (TRUMY)?
Short answer
The distress and quality screens read Altman Z 4.51 · Piotroski F 5. Trailing ratios: ROE 10.6% · ROA 6.9% · current ratio 2.19 · earnings yield 4.8% · free-cash-flow yield 5.6%.
What should you watch next at Terumo (TRUMY)?
Short answer · as of
The next earnings report is expected on Nov 11, 2026.
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 0.0% Period end Jun 30, 2026
- Previous quarter · ownership
- 0.0% Prior to period end Jun 30, 2026
- Reporting holders
- 7 Period end Jun 30, 2026
- Previous quarter · holders
- 7 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Boston Common Asset Management, LLC | 37,211 |
| Gamma Investing LLC | 9,607 |
| Rhumbline Advisers | 9,145 |
| Salomon & Ludwin, LLC | 1,697 |
| Pnc Financial Services Group, INC. | 113 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Terumo (TRUMY)?
Terumo Healthcare Stock: Key Questions Answered
Research dated 2026-09-12; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What does Terumo’s Cardiac and Vascular business sell?
It supplies guidewires, catheters, stents, intravascular imaging, neurovascular devices, stroke-treatment tools, cardiopulmonary systems, and vascular graft products. Demand is linked to cardiovascular and cerebrovascular procedures rather than routine equipment replacement alone.
How does Terumo’s Blood and Cell Technologies business make money?
The business sells blood bags, collection and automated processing systems, pathogen-reduction tools, apheresis systems, and cell-expansion platforms. Its commercial exposure follows blood collection, component processing, therapeutic apheresis, and cell-management activity.
Why does Terumo manufacture prefillable syringes for pharmaceutical companies?
Prefillable syringes and needles place Terumo inside pharmaceutical drug-packaging programs as a contract manufacturer. That activity differs from selling devices directly for procedures because demand follows the packaging and delivery requirements of drugmakers.
What is the TRUMY stock price today?
The last price recorded on this page for Terumo Corporation (TRUMY) is $14.44, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Does TRUMY pay a dividend?
Yes. Terumo Corporation (TRUMY) shows a trailing 12-month dividend yield of 0.80%, as of Oct 5, 2026, in the data on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (50 figures)
The 50 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 41 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $14.44 | FMP | Financial Modeling Prep (FMP) quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. | |
px.change | Change on the day | +1.40% | FMP | Financial Modeling Prep (FMP) quote | |
px.mcap | Market capitalization | $21.3B | FMP | Financial Modeling Prep (FMP) quote — Provider market cap uses the share class it prices; a company with more than one class may show a larger total elsewhere. Market cap record date: 2026-10-05. Source capture time was not supplied. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
earn.next | Next earnings date | Nov 11, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
id.business_summary | Business description (FMP excerpt) | Terumo Corporation is a global medical technology company dedicated to the manufacturing and sale of a wide array of medical products and equipment, operating through three distinct business segments: Cardiac and Vascular… | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | +$0.20 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 20.93 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 3.7K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.23 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Medical Devices | FMP | Financial Modeling Prep (FMP) company profile | |
id.hq | Headquarters | 2-44-1, Hatagaya, Tokyo, TY, 151-0072, JP | FMP | Financial Modeling Prep (FMP) company profile | |
id.employees | Employees | 30,207 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Hikaru Samejima | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_revenue | Revenue, Q1 FY2027 | $1.97B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q1 FY2027 | $445M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
earn.history.depth.2026-08-07.revenue_actual | Revenue · reported — report date 2026-08-07 | $1.96B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-07.revenue_estimated | Revenue · estimate — report date 2026-08-07 | $1.84B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-07.eps_actual | EPS · reported — report date 2026-08-07 | $0.3000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-07.eps_estimated | EPS · estimate — report date 2026-08-07 | $0.1700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-15.revenue_actual | Revenue · reported — report date 2026-05-15 | $1.89B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-15.revenue_estimated | Revenue · estimate — report date 2026-05-15 | $1.84B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-15.eps_actual | EPS · reported — report date 2026-05-15 | $0.1100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-15.eps_estimated | EPS · estimate — report date 2026-05-15 | $0.1100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-13.revenue_actual | Revenue · reported — report date 2026-02-13 | $1.93B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-13.revenue_estimated | Revenue · estimate — report date 2026-02-13 | $1.86B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-13.eps_actual | EPS · reported — report date 2026-02-13 | $0.1400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-13.eps_estimated | EPS · estimate — report date 2026-02-13 | $0.1453 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-12.revenue_actual | Revenue · reported — report date 2025-11-12 | $1.78B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-12.revenue_estimated | Revenue · estimate — report date 2025-11-12 | $1.75B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-12.eps_actual | EPS · reported — report date 2025-11-12 | $0.1541 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-12.eps_estimated | EPS · estimate — report date 2025-11-12 | $0.1611 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q1 FY2027 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
own.institutions.depth.ownership_pct | Institutional ownership | 0.0% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 0.0% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 7 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 7 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Boston Common Asset Management, LLC — shares in provider snapshot | 37,211 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Gamma Investing LLC — shares in provider snapshot | 9,607 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Rhumbline Advisers — shares in provider snapshot | 9,145 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Salomon & Ludwin, LLC — shares in provider snapshot | 1,697 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Pnc Financial Services Group, INC. — shares in provider snapshot | 113 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 4 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $12.08 – $17.81 | UNRECORDED | Stored company-profile observation — Captured 2026-10-06 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 2 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-06 | |
fin.scores | Distress and quality screens | Altman Z 4.51 · Piotroski F 5 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-05 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 10.6% · ROA 6.9% · current ratio 2.19 · earnings yield 4.8% · free-cash-flow yield 5.6% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 4 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $0.12 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 1 split-adjusted declared dividend with an ex-date in the 365 days to 2026-10-06, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 0.80% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-08-07.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($1.96B) with the recorded estimate ($1.84B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-07.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($0.3000) with the recorded estimate ($0.1700) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 1 fact from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
gap.statement_currency | Statement currency limitation | Detailed statement figures are not shown because their conversion to USD has not been verified. | OURS | Stock Expert AI currency-basis check |
Fact-family notes
- Earnings-history note. Source series as of 2026-08-07. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-07.revenue_actual,earn.history.depth.2026-08-07.revenue_estimated,earn.history.depth.2026-08-07.revenue_actual.comparison,earn.history.depth.2026-08-07.eps_actual.comparison,earn.history.depth.2026-08-07.eps_actual,earn.history.depth.2026-08-07.eps_estimated,earn.history.depth.2026-05-15.revenue_actual,earn.history.depth.2026-05-15.revenue_estimated,earn.history.depth.2026-05-15.eps_actual,earn.history.depth.2026-05-15.eps_estimated,earn.history.depth.2026-02-13.revenue_actual,earn.history.depth.2026-02-13.revenue_estimated,earn.history.depth.2026-02-13.eps_actual,earn.history.depth.2026-02-13.eps_estimated,earn.history.depth.2025-11-12.revenue_actual,earn.history.depth.2025-11-12.revenue_estimated,earn.history.depth.2025-11-12.eps_actual,earn.history.depth.2025-11-12.eps_estimated.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-12
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Terumo Corporation is a global medical technology company dedicated to the manufacturing and sale of a wide array of medical products and equipment, operating through three distinct business segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular division provides critical devices for cardiovascular and cerebrovascular interventions, including angiographic guidewires, various catheters (angiographic, PTCA balloon, imaging), introducer sheaths, vascular closure devices, coronary and self-expanding peripheral stents, and intravascular ultrasound systems; it also develops specialized tools for cerebral aneurysm treatment like coils, stents, and intrasaccular devices, as well as embolization systems, aspiration catheters, and clot retrievers for ischemic stroke, further supplying oxygenators, cardio-pulmonary bypass systems, and artificial vascular and stent grafts. The Medical Care Solutions segment offers a comprehensive range of general medical products such as syringes, infusion and syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, pain management and nutritional products, and adhesion barriers; for patient self-care, it provides blood glucose monitoring systems, disposable needles for pen-injectors, insulin patch pumps, blood pressure monitors, and digital thermometers, while also performing contract manufacturing for pharmaceutical companies, producing prefillable syringes and needles for drug packaging. The Blood and Cell Technologies division focuses on innovations in blood and cell management, offering products such as blood bags, component collection systems, automated blood processing and pathogen reduction systems, centrifugal apheresis systems, and cell expansion systems. Originally founded in 1921 as Sekisen Ken-onki Corporation, the company adopted the name Terumo Corporation in October 1974 and maintains its headquarters in Tokyo, Japan. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
Data provided for informational purposes only.